Shares

CME Group Inc. (NASDAQ:CME) Shares Sold by Cypress Capital Group

Cypress Capital Group reduced its stake in shares of CME Group Inc. (NASDAQ:CMEGet Rating) by 7.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,508 shares of the financial services provider’s stock after selling 3,509 shares during the quarter. CME Group comprises approximately 1.3% of Cypress Capital Group’s portfolio, making the stock its 18th largest holding. Cypress Capital Group’s holdings in CME Group were worth $7,530,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

→ New “Vertical” Technology Solves Solar Power’s Major Flaw (From Investing Trends)

Several other hedge funds and other institutional investors have also recently bought and sold shares of CME. West Family Investments Inc. acquired a new position in CME Group in the third quarter valued at $381,000. Bank Julius Baer & Co. Ltd Zurich increased its stake in CME Group by 2.2% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 562,310 shares of the financial services provider’s stock valued at $99,602,000 after purchasing an additional 12,277 shares during the period. Foyston Gordon & Payne Inc increased its stake in CME Group by 88.3% in the third quarter. Foyston Gordon & Payne Inc now owns 25,495 shares of the financial services provider’s stock valued at $4,516,000 after purchasing an additional 11,952 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of CME Group by 11.4% in the third quarter. Russell Investments Group Ltd. now owns 719,450 shares of the financial services provider’s stock valued at $127,575,000 after acquiring an additional 73,726 shares in the last quarter. Finally, Gratus Capital LLC boosted its holdings in shares of CME Group by 10.1% in the third quarter. Gratus Capital LLC now owns 57,632 shares of the financial services provider’s stock valued at $10,208,000 after acquiring an additional 5,289 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Credit Suisse Group raised shares of CME Group from a “neutral” rating to an “outperform” rating and set a $191.00 target price on the stock in a report on Thursday, January 5th. Piper Sandler lowered their target price on shares of CME Group from $270.00 to $250.00 and set an “overweight” rating on the stock in a report on Monday, December 19th. StockNews.com assumed coverage on shares of CME Group in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft lowered their target price on shares of CME Group from $207.00 to $200.00 in a report on Wednesday, January 11th. Finally, UBS Group decreased their price objective on shares of CME Group from $226.00 to $220.00 in a report on Thursday, January 5th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, CME Group presently has a consensus rating of “Hold” and an average price target of $220.73.

Insider Buying and Selling at CME Group

In related news, Director William R. Shepard acquired 48,645 shares of CME Group stock in a transaction on Friday, November 4th. The shares were purchased at an average cost of $170.00 per share, for a total transaction of $8,269,650.00. Following the purchase, the director now directly owns 247,843 shares of the company’s stock, valued at approximately $42,133,310. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.30% of the stock is currently owned by insiders.

CME Group Trading Up 0.2 %

CME stock traded up $0.27 on Monday, hitting $175.33. 263,362 shares of the company were exchanged, compared to its average volume of 1,733,612. CME Group Inc. has a twelve month low of $166.54 and a twelve month high of $256.94. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. The business’s fifty day moving average is $174.21 and its two-hundred day moving average is $184.07. The stock has a market capitalization of $63.07 billion, a price-to-earnings ratio of 23.82, a price-to-earnings-growth ratio of 3.53 and a beta of 0.40.

CME Group (NASDAQ:CMEGet Rating) last announced its earnings results on Wednesday, October 26th. The financial services provider reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.93 by $0.05. The business had revenue of $1.23 billion during the quarter, compared to the consensus estimate of $1.23 billion. CME Group had a net margin of 54.01% and a return on equity of 10.06%. As a group, research analysts forecast that CME Group Inc. will post 7.93 earnings per share for the current year.

CME Group Increases Dividend

The business also recently disclosed a None dividend, which was paid on Wednesday, January 18th. Shareholders of record on Wednesday, December 28th were paid a dividend of $4.50 per share. This is an increase from CME Group’s previous None dividend of $3.25. The ex-dividend date was Tuesday, December 27th. CME Group’s dividend payout ratio is 54.42%.

CME Group Profile

(Get Rating)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income products.

See Also

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CMEGet Rating).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider CME Group, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CME Group wasn’t on the list.

While CME Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.